BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36439433)

  • 1. PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma.
    Hadrava Vanova K; Uher O; Meuter L; Ghosal S; Talvacchio S; Patel M; Neuzil J; Pacak K
    Front Oncol; 2022; 12():1045517. PubMed ID: 36439433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
    Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
    J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma/Paraganglioma.
    Yu A; Xu X; Pang Y; Li M; Luo J; Wang J; Liu L
    Lab Invest; 2023 Sep; 103(9):100210. PubMed ID: 37406931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
    Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation Profile of Aggressive Pheochromocytoma and Paraganglioma with Comparison of TCGA Data.
    Choi YM; Lim J; Jeon MJ; Lee YM; Sung TY; Hong EG; Lee JY; Jang SJ; Kim WG; Song DE; Chun SM
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
    Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity.
    Vit O; Patel M; Musil Z; Hartmann I; Frysak Z; Miettinen M; Pacak K; Petrak J
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain landscapes of somatic NF1 mutations in pheochromocytoma and paraganglioma.
    Tabebi M; Frikha F; Volpe M; Gimm O; Söderkvist P
    Gene; 2023 Jul; 872():147432. PubMed ID: 37062455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
    Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1034-43. PubMed ID: 26796762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
    Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
    Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas.
    Petenuci J; Guimaraes AG; Fagundes GFC; Benedetti AFF; Afonso ACF; Pereira MAA; Zerbini MCN; Siqueira S; Yamauchi F; Soares SC; Srougi V; Tanno FY; Chambo JL; Lopes RI; Denes FT; Hoff AO; Latronico AC; Mendonca BB; Fragoso MCBV; Almeida MQ
    Clin Endocrinol (Oxf); 2021 Jul; 95(1):117-124. PubMed ID: 33745191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
    Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
    Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
    Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
    Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
    Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
    J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
    Smestad JA; Maher LJ
    BMC Cancer; 2019 Jun; 19(1):619. PubMed ID: 31234811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.